Switch theme
Sign up to access all valuation multiples
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
2019
64
Last FY Revenue n/a
LTM EBITDA -$83.4M
$36.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jasper Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$83.4M.
In the most recent fiscal year, Jasper Therapeutics achieved revenue of n/a and an EBITDA of -$74.9M.
Jasper Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jasper Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$83.4M | XXX | -$74.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$83.5M | XXX | -$76.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$79.5M | XXX | -$71.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jasper Therapeutics's stock price is $6.
Jasper Therapeutics has current market cap of $82.6M, and EV of $36.4M.
See Jasper Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $36.4M | $82.6M | XXX | XXX | XXX | XXX | $-5.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jasper Therapeutics has market cap of $82.6M and EV of $36.4M.
Jasper Therapeutics's trades at n/a EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Jasper Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jasper Therapeutics has a P/E ratio of -1.0x.
See valuation multiples for Jasper Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $82.6M | XXX | $82.6M | XXX | XXX | XXX |
| EV (current) | $36.4M | XXX | $36.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJasper Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Jasper Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jasper Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jasper Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jasper Therapeutics acquired XXX companies to date.
Last acquisition by Jasper Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Jasper Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jasper Therapeutics founded? | Jasper Therapeutics was founded in 2019. |
| Where is Jasper Therapeutics headquartered? | Jasper Therapeutics is headquartered in United States of America. |
| How many employees does Jasper Therapeutics have? | As of today, Jasper Therapeutics has 64 employees. |
| Who is the CEO of Jasper Therapeutics? | Jasper Therapeutics's CEO is Mr. Ronald A. Martell. |
| Is Jasper Therapeutics publicy listed? | Yes, Jasper Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Jasper Therapeutics? | Jasper Therapeutics trades under JSPR ticker. |
| When did Jasper Therapeutics go public? | Jasper Therapeutics went public in 2021. |
| Who are competitors of Jasper Therapeutics? | Similar companies to Jasper Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jasper Therapeutics? | Jasper Therapeutics's current market cap is $82.6M |
| Is Jasper Therapeutics profitable? | Yes, Jasper Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jasper Therapeutics? | Jasper Therapeutics's last 12 months EBITDA is -$83.4M. |
| What is the current EV/EBITDA multiple of Jasper Therapeutics? | Current EBITDA multiple of Jasper Therapeutics is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
